This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (15)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Medical Ethics  • Randomized Controlled Trial  • Alert me on articles by topic

Stuart J. Pocock, PhD

JAMA. 2005;294:2228-2230.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of JAMA, Montori and colleagues¹ provide a valuable extensive and critical systemic review of clinical trials that were stopped early for benefit. Readers of the reports of such trials often feel a sense of excitement, especially when phrases such as "a major treatment advance," "ethical need to stop the inferior treatment," and "vital to tell the world immediately" are used. However, experience suggests that early results and enthusiasm, especially for modestly sized trials terminated early for apparent major benefit, are often moderated as subsequent reports arise.²

The skeptic should ask first whether correct and appropriate structures were in place for analyzing and reviewing, and making decisions based on, the trial’s accumulating interim data. Having the members of an effective independent data monitoring committee (DMC) or data and safety monitoring board as the only individuals accessing and interpreting interim data split by treatment . . . [Full Text of this Article]

Author Affiliation: Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, England.

RELATED ARTICLE

Randomized Trials Stopped Early for Benefit: A Systematic Review
Victor M. Montori, P. J. Devereaux, Neill K. J. Adhikari, Karen E. A. Burns, Christoph H. Eggert, Matthias Briel, Christina Lacchetti, Teresa W. Leung, Elizabeth Darling, Dianne M. Bryant, Heiner C. Bucher, Holger J. Schünemann, Maureen O. Meade, Deborah J. Cook, Patricia J. Erwin, Amit Sood, Richa Sood, Benjamin Lo, Carly A. Thompson, Qi Zhou, Edward Mills, and Gordon H. Guyatt
JAMA. 2005;294(17):2203-2209.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Stopping a trial early in oncology: for patients or for industry?
Trotta et al.
Ann Oncol 2008;19:1347-1353.
ABSTRACT | FULL TEXT  

Effect of Doxazosin Gastrointestinal Therapeutic System as Third-Line Antihypertensive Therapy on Blood Pressure and Lipids in the Anglo-Scandinavian Cardiac Outcomes Trial
Chapman et al.
Circulation 2008;118:42-48.
ABSTRACT | FULL TEXT  

Stopping Trials for Benefit Can (Sometimes) Benefit Patients
Pater et al.
JCO 2008;26:2787-2788.
FULL TEXT  

When Should Data and Safety Monitoring Committees Share Interim Results in Cardiovascular Trials?
Borer et al.
JAMA 2008;299:1710-1712.
FULL TEXT  

Cooling for Neonatal Hypoxic Ischemic Encephalopathy: Do We Have the Answer?
Kirpalani et al.
Pediatrics 2007;120:1126-1130.
FULL TEXT  

Ethical Issues in Stopping Randomized Trials Early Because of Apparent Benefit
Mueller et al.
ANN INTERN MED 2007;146:878-881.
ABSTRACT | FULL TEXT  

Current controversies in data monitoring for clinical trials
Pocock
Clin Trials 2006;3:513-521.
ABSTRACT  

A public health perspective on research ethics
Buchanan and Miller
J. Med. Ethics 2006;32:729-733.
ABSTRACT | FULL TEXT  

Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis
Mas et al.
NEJM 2006;355:1660-1671.
ABSTRACT | FULL TEXT  

Renin angiotensin blockade in heart failure with preserved ejection fraction: the signal gets stronger
McMurray
Eur Heart J 2006;27:2257-2259.
FULL TEXT